Glass Lewis and Institutional Shareholder Services advise against giving retail tycoon board role
Barington Capital and investment partner Thor urge measures to revive US department store chain’s flagging share price
Financier sparked backlash with takeover attempts but country has become more receptive to foreign funds
Disputes between company boards and their biggest investors can drag on and on
Chris Boshoff played role in drugmaker’s acquisition of Seagen, which has been criticised by investor
With Japan’s hotel market booming, now would be a good time for the group to consider selling the Park Hyatt Tokyo
Stock surge at boutique PJT Partners values Blackstone co-founder Stephen Schwarzman’s stake at over $900mn
US activist investor plans to push Japanese company to offload some of its $9bn real estate portfolio
Drugstore operator’s concession follows recent replacement of its chief and leadership overhaul in its insurance unit
Asset manager gives investors greater say on proxy votes as it tries to navigate backlash to ‘woke’ policies
Conservative groups and lawmakers eye restrictions on proxy firms as new era in Washington emboldens their critics
MediaForEurope says it wants broadcaster to make ‘radical choices’
Plus, an activist takes a stake in Nissan and the $20bn Verizon-Frontier deal goes down to the wire
US activist investor wants to split the conglomerate’s aerospace and automation businesses
Hedge fund Effissimo Capital is known for high-profile campaigns against big Japanese companies
Plus, hedge funds fight over a financial lifeline for Thames Water and India’s once-hot IPO market loses momentum
London-based portfolio manager worked on some of activist hedge fund’s most high-profile campaigns
Drugmaker boosts full-year sales and profit forecasts after reporting better than expected earnings
Investors in French media group to vote on proposal in December
Widely feared boss of Starboard Value often befriends the corporate leaders he is targeting
Years after Pfizer’s Covid-era success, the US pharmaceutical giant is facing an activist campaign
Activist investor with $1bn stake says leaders should be held responsible for inadequate returns
Stakebuilding by Palliser Capital follows Elliott Management's move on sector peer Mitsui Fudosan
Boutique adviser’s work for two former executives has threatened its lucrative ties to the vaccine maker
Plus, the senior bankers at the centre of HSBC’s plans to cut costs and 7-Eleven’s latest tactic to fend of a $47bn hostile takeover
